These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 16610789

  • 1. Molecular docking-based study of vasopressin analogues modified at positions 2 and 3 with N-methylphenylalanine: influence on receptor-bound conformations and interactions with vasopressin and oxytocin receptors.
    Slusarz MJ, Sikorska E, Slusarz R, Ciarkowski J.
    J Med Chem; 2006 Apr 20; 49(8):2463-9. PubMed ID: 16610789
    [Abstract] [Full Text] [Related]

  • 2. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ, Giełdoń A, Slusarz R, Ciarkowski J.
    J Pept Sci; 2006 Mar 20; 12(3):180-9. PubMed ID: 16114100
    [Abstract] [Full Text] [Related]

  • 3. Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin-modeling of an activated state.
    Slusarz MJ, Slusarz R, Ciarkowski J.
    J Pept Sci; 2006 Mar 20; 12(3):171-9. PubMed ID: 16114099
    [Abstract] [Full Text] [Related]

  • 4. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ, Slusarz R, Ciarkowski J.
    Biopolymers; 2006 Apr 05; 81(5):321-38. PubMed ID: 16333859
    [Abstract] [Full Text] [Related]

  • 5. Interactions of vasopressin and oxytocin receptors with vasopressin analogues substituted in position 2 with 3,3'-diphenylalanine--a molecular docking study.
    Slusarz MJ, Sikorska E, Slusarz R.
    J Pept Sci; 2013 Feb 05; 19(2):118-26. PubMed ID: 23303737
    [Abstract] [Full Text] [Related]

  • 6. Conformational studies of vasopressin analogues modified with N-methylphenylalanine enantiomers in dimethyl sulfoxide solution.
    Sikorska E, Slusarz MJ, Lammek B.
    Biopolymers; 2006 Aug 15; 82(6):603-14. PubMed ID: 16557499
    [Abstract] [Full Text] [Related]

  • 7. Influence of bulky 3,3'-diphenylalanine enantiomers replacing position 2 of AVP analogues on their conformations: NMR and molecular modeling studies.
    Sikorska E, Kwiatkowska A, Sobolewski D, Slusarz R, Slusarz MJ.
    Eur J Med Chem; 2010 Sep 15; 45(9):4065-73. PubMed ID: 20580135
    [Abstract] [Full Text] [Related]

  • 8. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
    Giełdoń A, Kaźmierkiewicz R, Slusarz R, Ciarkowski J.
    J Comput Aided Mol Des; 2001 Dec 15; 15(12):1085-104. PubMed ID: 12160092
    [Abstract] [Full Text] [Related]

  • 9. Molecular modeling of the oxytocin receptor/bioligand interactions.
    Politowska E, Czaplewski C, Ciarkowski J.
    Acta Biochim Pol; 1999 Dec 15; 46(3):581-90. PubMed ID: 10698266
    [Abstract] [Full Text] [Related]

  • 10. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 11. Residues in the hydrophilic face of putative helix 8 of oxytocin receptor are important for receptor function.
    Zhong M, Navratil AM, Clay C, Sanborn BM.
    Biochemistry; 2004 Mar 30; 43(12):3490-8. PubMed ID: 15035619
    [Abstract] [Full Text] [Related]

  • 12. Investigation of cis/trans ratios of peptide bonds in AVP analogues containing N-methylphenylalanine enantiomers.
    Sikorska E, Slusarz MJ, Slusarz R, Kowalczyk W, Lammek B.
    J Pept Sci; 2006 Jan 30; 12(1):13-24. PubMed ID: 15959924
    [Abstract] [Full Text] [Related]

  • 13. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains.
    Zhorov BS, Ananthanarayanan VS.
    Arch Biochem Biophys; 2000 Mar 01; 375(1):31-49. PubMed ID: 10683246
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Mar 01; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 19. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore.
    Axe FU, Bembenek SD, Szalma S.
    J Mol Graph Model; 2006 May 01; 24(6):456-64. PubMed ID: 16386444
    [Abstract] [Full Text] [Related]

  • 20. Conformational aspects of differences in requirements for oxytocin and vasopressin receptors.
    Oldziej S, Ciarkowski J, Liwo A, Shenderovich MD, Grzonka Z.
    J Recept Signal Transduct Res; 1995 May 01; 15(1-4):703-13. PubMed ID: 8903974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.